The IRX-2 regimen combined with nivolumab in recurrent/metastatic solid tumors: A phase 1b study to evaluate the safety, determine recommended phase 2 dose (RP2D), and investigate the biologic and clinical activity

Category Primary study
JournalJournal of Clinical Oncology
Year 2019
This article has no abstract
Epistemonikos ID: 977d8c11e32f121a02bf817433f34fe56f9b4143
First added on: Feb 11, 2025